Management of Thyroid-Induced Atrial Fibrillation

Primary Treatment Strategy

The European Society of Cardiology recommends that the cornerstone of managing atrial fibrillation caused by thyroid disorders is restoring a euthyroid state, which typically results in spontaneous reversion to sinus rhythm in over half of patients 1, 2

The European Society of Cardiology mandates beta-blockers as the first-line treatment for controlling ventricular rate in thyrotoxic AF, with a Class I recommendation 1, 2
The European Society of Cardiology recommends that intravenous beta-blockers are particularly critical in thyroid storm, where high doses may be required to achieve adequate rate control 1, 3
The American Heart Association notes that beta-blockers provide dual benefit by controlling heart rate and blocking peripheral conversion of T4 to T3, although this fact is from a less preferred source 4

The European Society of Cardiology recommends that oral anticoagulation (INR 2-3) is mandatory in thyrotoxic AF to prevent thromboembolism, with a Class I recommendation, using the same risk stratification as other AF patients 1, 2
The European Society of Cardiology recommends that once euthyroid state is restored, continue anticoagulation based on standard stroke risk factors (CHA₂DS₂-VASc score), not thyroid status alone 1, 2

The European Society of Cardiology recommends that attempted cardioversion should be deferred until approximately 4 months after achieving euthyroid state, with a Class I recommendation 2
The European Society of Cardiology notes that normalizing thyroid function prior to cardioversion is essential to reduce relapse risk, with a Class I recommendation 2

The American College of Cardiology recommends that amiodarone must be avoided or discontinued in patients with thyroid storm due to risk of exacerbating thyrotoxicosis and increasing cardiovascular complications including myocardial infarction, although this fact is from a less preferred source 3
The European Society of Cardiology recommends that immediate direct current cardioversion is required for hemodynamically unstable patients with rapid ventricular response, regardless of thyroid status 1, 3

The European Society of Cardiology recommends that during active treatment, monitor for signs of levothyroxine overtreatment in hypothyroid patients, including tachycardia, palpitations, or worsening AF, although this fact is from a less preferred source 5
The European Society of Cardiology recommends that target TSH in normal reference range (0.5-2.5 mIU/L) when treating amiodarone-induced hypothyroidism, although this fact is from a less preferred source 5
The European Society of Cardiology recommends that thyroid function monitoring should be continued as thyrotoxicosis may recur after cessation of amiodarone therapy 2
The European Society of Cardiology recommends that anticoagulation needs should be reassessed once euthyroid state is maintained, transitioning to standard AF risk stratification 1, 2